| Literature DB >> 35646849 |
Hengyi Wang1, Yuanliang Xia1, Baoqin Li1, Yuehong Li1, Changfeng Fu1.
Abstract
Spinal cord injury (SCI) is a severe and traumatic disorder that ultimately results in the loss of motor, sensory, and autonomic nervous function. After SCI, local immune inflammatory response persists and does not weaken or disappear. The interference of local adverse immune factors after SCI brings great challenges to the repair of SCI. Among them, microglia, macrophages, neutrophils, lymphocytes, astrocytes, and the release of various cytokines, as well as the destruction of the extracellular matrix are mainly involved in the imbalance of the immune microenvironment. Studies have shown that immune remodeling after SCI significantly affects the survival and differentiation of stem cells after transplantation and the prognosis of SCI. Recently, immunological reconstruction strategies based on biomaterials have been widely explored and achieved good results. In this review, we discuss the important factors leading to immune dysfunction after SCI, such as immune cells, cytokines, and the destruction of the extracellular matrix. Additionally, the immunomodulatory strategies based on biomaterials are summarized, and the clinical application prospects of these immune reconstructs are evaluated.Entities:
Keywords: cytokines; extracellular matrix; immune cell; immune microenvironment; reactive oxygen species; spinal cord injury
Year: 2022 PMID: 35646849 PMCID: PMC9136098 DOI: 10.3389/fbioe.2022.812340
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
SCHEME 1Schematic diagram of biomaterials regulating the local immune microenvironment after spinal cord injury and promoting nerve regeneration and myelination.
Physical properties and functions of polymer biomaterials.
| Materials | Carrying substance | Fabrication technology | Properties | Function | References |
|---|---|---|---|---|---|
| Chitosan-FPHS |
| Take off the acetylation | Cytocompatibility Biodegradability non-toxic | Promote macrophage polarization to M2 phenotype, Reduce scar formation, Inhibit astrocyte proliferation |
|
| NHC |
| The physical blending | Excellent mechanical strength and porosity | Increase the ratio of M2 macrophages and promote angiogenesis, axon growth and neurogenesis |
|
| IOA |
| Enzymatic hydrolysis | biocompatibility | Promote macrophage polarization to M2 phenotype |
|
| OPF+ | Schwann cells | Azeotropic distillation, crosslinking | Excellent compression and bending modulus | Promote macrophage polarization to M2 phenotype, Reduces stromal scarring, cyst formation, astrocyte reactivity, CSPG deposition, and myelin sheath debris |
|
| PLG | IL-10,NT-3, IL-4 | Gas foaming/particulate leaching, Electrospinning technology | biodegradable | Alter macrophage phenotype, Promote axon growth and function recovery, Inhibits the release of inflammatory factors | ( |
| Poly(lactide-coglycolide) NPs |
| Gas foaming/particulate leaching, Steam method | biodegradable | The number of M2 macrophages was up-regulated, Reduce gelatinous scars, Axon regeneration, Recovery of motor function |
|
| carbomer/agarose/polyethylene glycol (PEG) based hydrogel | HMSC |
| Biocompatible, biodegradable | Promote macrophage polarization to M2 phenotype, Protective neuron |
|
| CS | MSC | Chemical extraction, freeze drying | Nerve guide | Promote macrophage polarization to M2 phenotype, Protective neuron, Reduce gelatinous scars, Inhibit astrocyte proliferation |
|
| PLLA | Ibuprofen and T3 | Electrostatic spinning | Biocompatibility biodegradability | Reduce the number of M1-type macrophages |
|
| MoS2@PEG | ET | Microwave-assisted hydrothermal method | Biocompatibility biodegradability | Promote macrophage polarization to M2 phenotype, Protective neuron, Improved motor function |
|
| DS | MH | self-assembly | Biocompatibility | Promote macrophage polarization to M2 phenotype, Improved motor function |
|
| Type I collagen |
| Freeze drying | Biocompatibility, low antigenicity biodegradability | Reduce phagocyte recruitment |
|
| Type I collagen | NT-3 | Freeze drying | Biocompatibility, low antigenicity biodegradability | Reduced macrophage/microglia activity, Promote axon growth, Reduce scar formation |
|
| PTNP | Piceatannol spleen tyrosine kinase inhibitor superparamagnetic iron oxide | Ultrasonic fusion Freeze-thaw cycle | Biocompatibility | Reduce neutrophil infiltration |
|
| DOX-hyd-BSA NPs | DOX | Desolvation | Biocompatibility | Reduce neutrophil infiltration |
|
| ASC | BMSC |
| Biocompatibility | Reduce T lymphocyte recruitment, Promote functional recovery |
|
| CCH | Serp-1 | Remove the ion Freeze drying | Biocompatibility, low antigenicity biodegradability | Reduce T lymphocyte recruitment |
|
| PCL/BSA | DEXP | Electrospinning fibers | Good mechanical properties, Biocompatibility Biodegradability The hydrophilic | Inhibit astrocyte proliferation, Reduce oligodendrocyte apoptosis |
|
| MCM | IL-10 |
| Biological adsorption, Good solubility | Inhibit inflammatory cytokines, Promote anti-inflammatory cell proliferation, Allows axons to grow |
|
| MSaP-aL/p | Il-4 plasmid liposomes | Electrospinning technology | Acid responsiveness | Promote the secretion of anti-inflammatory factors, Promote macrophage/microglia M2 polarization, Inhibit astrocyte activation |
|
| PCL/fibrin gel | MPSS | Nano precipitation technology | Biodegradability Locally sustained drug release | Inhibit IL-6 and IL-1β release |
|
| IKVAV PA | BDNF | Automatic solid phase synthesis method | Biocompatibility Biodegradability | Inhibit inflammation and astrocyte proliferation |
|
| SF/AGs/GDNF | GDNF |
| Low immunogenicity | Inhibit il-1 β, IL-6 and TNF-α release |
|
| PLGA |
|
| Biodegradability | Reduce CSPG accumulation |
|
| Ac-DEX | PTX | microprecipitation method | Good release rate | Reduce CSPG accumulation |
|
| AST-PCL | AST |
|
| Down-regulation of MMP-9 secretion, reduction of neutrophil infiltration |
|
| PEG |
| Water/oil emulsion method, free radical polymerization | The hydrophilic | Inhibits ROS production |
|
| PSA | MH | Acylation reaction, self-assembly | Biocompatibility | Antioxidation, Anti-inflammatory effects |
|
| PCL | MLT | Electrospinning technology, Multilayer molding process | Excellent mechanical properties, porosity | Correcting mitochondrial function reduces oxidative stress |
|
| MnO2 NPs | MnO2 | Crosslinking, biomineralization | Biocompatibility | Inhibits ROS production |
|
| SeNPs@GM1/TMP | Selenium, GM1, TMP |
|
| Inhibits ROS production |
|
IL-4, Interleukin-4; IL-10, Interleukin-10; NT-3, Neurotrophin-3; hMSC, humanbonemarrow-deftvedmesenchymalstemcell; MSC, mesenchymal stem cell; BMSC, bone marrow stromal cells; T3, triiodothyronine; ET, etanercept; DS, dextran sulfate; MH, minocycline hydrochloride; DOX, doxorubicin; Serp-1, serine protease Inhibitors-1; DEXP, dexamethasone sodium phosphate; MPSS, methylprednisolone sodium succinate; BDNF, brain derived neurotrophic factor; GDNF, Glial cell line-Derived Neurotrophic Factor; PTX, paclitaxel; AST, astragaloside; MLT, melatonin; TMP, tetramethylpyrazine; GM1, gangliosides.
FIGURE 1Biomaterials directly regulate the polarization of macrophages/microglia. (A) The animals were treated with PBS (a1 and a3) and iOA hydrogel (a2 and a4) for 1 week, and the cross-section of the spinal cord was stained for macrophage markers. CCR7 is stained for M1 phenotype cells, and CD206 is stained for M2 phenotype cells. (B) The ratio of M1 to M2 phenotypic cells changed from 1.88 ± 0.406 for PBS control to 0.635 ± 0.085 for iOA, a three-fold decrease (*p < 0.05; n = 4). (C) The density of total F4/80 + macrophages in the lesion. (D) Quantitative analysis showed that NPs up-regulated the expression of CD206 + cells. (E) The ratio of M2 to the total number of macrophages was significantly up-regulated in the NP group. Reproduced with permission from (60, 63).
FIGURE 2Regulation of macrophages/microglia by biomaterials loaded with different substances. (A) SCI model construction, 3 mm segment of left spinal cord of rat T9 was removed, and CS or CS composite MSCs were implanted. (B) CD68, iNOS and CD206 immunohistochemical staining of spinal cord slices in the treatment group. (C) The bar graph shows the number of CD68, iNOS and CD206 positive cells at 3, 12, and 28 days after surgery. (D) M1/M2 ratio of untreated control group, blank gel group, local MH gel group and whole body IP treatment group. Reproduced with permission from (65, 70).
FIGURE 3Regulation of neutrophils and lymphocytes by biological materials. (A) Quantitative analysis of CD3+ cells in different treatment groups and immunohistochemical staining of CD3+ cells on day 28 under the same conditions. (B) Changes of neutrophils (106/L) in the experimental group and the control group at different time periods. (C) T lymphocytes (CD5) showing significant differences for the BMSCs + ASC group compared with the ASC group (*p < 0.05) and control group (#p < 0.05) at 2 weeks after surgery. (D) Histological characteristics of different groups on the 28th day after operation. d1 and d2 were controls: fibrotic tissue infiltration and neuron necrosis were seen. d3 and d4 were experimental groups: the injury site was filled with neatly arranged white matter fibers and mild inflammation. Reproduced with permission from (82, 84, 86).
FIGURE 4Regulation of astrocytes by biomaterials. (A) Preparation of chitosan-FPHS. (B,C) Immunofluorescence staining was performed in the control group and the treatment group 4 weeks after surgery. (D) Comparison of primary lesion area between the treatment group and the control group. (E) Western blot was used to analyze GFAP levels in the treatment group and the control group at different time points after surgery. Reproduced with permission from (56).
FIGURE 5Biomaterials containing anti-inflammatory factors. (A) Schematic diagram and application method of composite material. (B) Evaluation of immunomodulation of composite materials on the 7th day after operation. ELISA method to detect serum IL-4 (C), tumor necrosis factor-α (D) and IL-10 (E) levels. Reproduced with permission from (38).
FIGURE 6Regulation of immune microenvironment by biomaterials loaded with growth factors. (A) Anti-GFAP immunoreactivity in the injured site after 6 weeks of hydrogel treatment in different treatment groups. (B) Quantitative analysis of the fluorescence intensity of GFAP staining. (C) Western blot detection of inflammation-related markers at 4 and 8 weeks after treatment. A SCI group; B SF/AGs group; C SF/AGs/GDNF group; D SF/AGs/GDNF + hUCMSCs group. (D) Scaffold neurotrophic factor release curve. (E) Exercise scores of all treatment groups at different time points after treatment. Reproduced with permission from (110, 113).
FIGURE 7Regulation of undesirable components in extracellular matrix by biomaterials. (A) Immunohistochemical staining of CS56 (red) and GFAP (green) at 28 days after injury. (B) 13 weeks after SCI, PBS and IMP groups were immunostained with CS-56 and GFAP. (C,D) Cs-56 quantitative analysis of lesion area. Reproduced with permission from (119, 124).
FIGURE 8Biomaterials reverse the adverse immune microenvironment by removing harmful components from the extracellular matrix. (A) Simulate the cultivation of MSCs in a microenvironment containing ROS. (B) After labeling with dichlorodihydrofluorescein diacetate (DCFH-DA), quantify (b1) intracellular ROS levels in blank (b2, b3) and MnO2 NP points (b4, b5) hydrogels. (C) Use live/dead assay to analyze cell survival in the blank group (c2, c3) and treatment group (c4, c5), and quantify the stained area (c1). (D) Oxidative stress assessment of MLT/PCL and PCL catheters after surgery. (E) Relative level of GCLC. (F) Relative level of MnSOD. (G) Relative level of nNOS. Reproduced with permission from (139, 142).